Proton Therapy For Lymphomas: Current State Of The Art

References

• Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early- stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21:3601–3608.12913100
   PubMed Web of Science ®Google Scholar
• Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early un- favorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199–4206. doi:10.1200/JCO.2010.29.801820713848
   PubMed Web of Science ®Google Scholar
• Viviani S, Zinzani PL, Rambaldi A, et al. Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi: ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365:203–212. doi:10.1056/NEJMoa110034021774708
   PubMed Web of Science ®Google Scholar
• Mounier N, Brice P, Bologna S, et al. Lymphoma Study Association (LYSA): ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014;25:1622–1628. doi:10.1093/annonc/mdu18924827123
   PubMed Web of Science ®Google Scholar
• Horner M, Ries L, Krapcho M, et al. SEER cancer statistics review, 1975–2014. National Cancer Institute. 2017 Available from: https://seer.cancer.gov/csr/1975_2014/. Accessed September 21, 2019.
   Google Scholar
• Rutenberg MS, Flampouri S, Hoppe BS. Proton therapy for Hodgkin lymphoma. Curr Hematol Malig Rep. 2014;9:203–211. doi:10.1007/s11899-014-0212-724842407
   PubMed Web of Science ®Google Scholar
• Aleman BM, van Den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878–1886. doi:10.1182/blood-2006-07-03440517119114
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2015;34:235–243. doi:10.1200/JCO.2015.63.444426573075
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373:2499–2511. doi:10.1056/NEJMoa150594926699166
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–1607. doi:10.1056/NEJMoa140864825901426
   PubMed Web of Science ®Google Scholar
• Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative Stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2014;32:1188–1194. doi:10.1200/JCO.2013.51.929824637998
   PubMed Web of Science ®Google Scholar
• Ho CK, Flampouri S, Hoppe BS. Proton therapy in the management of lymphoma. Cancer J. 2014;20:387–392. doi:10.1097/PPO.000000000000007625415683
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89:854–862. doi:10.1016/j.ijrobp.2013.05.00523790512
   PubMed Web of Science ®Google Scholar
• Rwigema JM, Lagendijk JA, van der Laan PH, et al. A model-based approach to predict short-term toxicity benefits with proton therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2019;104:553–562. doi:10.1016/j.ijrobp.2018.12.05530625409
   PubMed Web of Science ®Google Scholar
• Illidge T, Specht L, Yahalom J, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma – target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2014;89:49–58. doi:10.1016/j.ijrobp.2014.01.00624725689
   PubMed Web of Science ®Google Scholar
• Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132:1635–1646. doi:10.1182/blood-2018-03-83763330108066
   PubMed Web of Science ®Google Scholar
• Edvardsson A, Kugele M, Alkner S, et al. Comparative treatment planning study for mediastinal Hosgkin’s lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy. Acta Oncol. 2019;58:95–104. doi:10.1080/0284186X.2018.151215330280626
   PubMed Web of Science ®Google Scholar
• Moyers MF, Miller DW, Bush DA, Slater JD. Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys. 2001;49:1429–1438. doi:10.1016/s0360-3016(00)01555-811286851
   PubMed Web of Science ®Google Scholar
• Urie M, Goitein M, Wagner M. Compensating for heterogeneities in proton radiation therapy. Phys Med Biol. 1984;29:553–566. doi:10.1088/0031-9155/29/5/0086330772
   PubMed Web of Science ®Google Scholar
• Pacelli R, Caroprese M, Palma G, et al. Technological evolution of radiation treatment: implications for clinical applications. Semin Oncol. 2019; in press. doi:10.1053/j.seminoncol.2019.07.004
   Google Scholar
• Hoppe BS, Flampouri S, Zaiden R, et al. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a Phase 2 study. Int J Radiat Oncol Biol Phys. 2014;89:1053–1059. doi:10.1016/j.ijrobp.2014.04.02924928256
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Tsai H, Larson G, et al. Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. Acta Oncol. 2016;55:1378–1380. doi:10.1080/0284186X.2016.119742227579554
   PubMed Web of Science ®Google Scholar
• Ntentas G, Dedeckova K, Andrlik M, et al. Clinical intensity modulated proton therapy for Hodgkin lymphoma: which patients benefit the most? Practical Rad Onc. 2019;9:179–197. doi:10.1016/j.prro.2019.01.006
   PubMed Web of Science ®Google Scholar
• Sachsman S, Flampouri S, Li Z, Lynch J, Mendenhall NP, Hoppe BS. Proton therapy in the management of non-Hodgkin lymphoma. Leuk Lymphoma. 2015;56:2608–2612. doi:10.3109/10428194.2015.101436425669925
   PubMed Web of Science ®Google Scholar
• Plastaras JP, Maity A, Flampouri S, et al. Bi-institutional report on consolidative proton therapy after initial chemotherapy for mediastinal diffuse large B-cell and primary mediastinal large B-cell lymphomas [abstract]. Int J Radiat Oncol Biol Phys. 2018;102(S3):E350. doi:10.1016/j.ijrobp.2018.07.1061
   Google Scholar
• Konig L, Bougatf N, Horner-Rieber J, et al. Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison. Strahlenther Onkol. 2019. doi:10.1007/s00066-019-01460-7
   PubMed Web of Science ®Google Scholar
• Tseng YD, Hoppe BS, Miller D, et al. Rates of toxicity and outcomes after mediastinal proton therapy for relapsed/refractory lymphoma [abstract]. Int J Radiat Oncol Biol Phys. 2017;99(S2):S62. doi:10.1016/j.ijrobp.2017.06.155
   Google Scholar
• Hoppe BS, Hill-Kayser CE, Tseng YD, et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Ann Oncol. 2017;28:2179–2184. doi:10.1093/annonc/mdx28728911093
   PubMed Web of Science ®Google Scholar
• Ricardi U, Dabaja B, Hodgson DC. Proton therapy in mediastinal Hodgkin lymphoma: moving form dosimetric prediction to clinical evidence. Ann Oncol. 2017;28:2049–2050. doi:10.1093/annonc/mdx35628911077
   PubMed Web of Science ®Google Scholar
• Winkfield KM, Gallotto S, Niemierko A, et al. Proton therapy for mediastinal lymphomas: an 8-year single-institution report [abstract]. Int J Radiat Oncol Biol Phys. 2015;93:E461. doi:10.1016/j.ijrobp.2015.07.1725
   Web of Science ®Google Scholar
• Wray J, Flampouri S, Slayton W, et al. Proton therapy for pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2016;63:1522–1526. doi:10.1002/pbc.2604427149120
   PubMed Web of Science ®Google Scholar
• Plastaras JP, Vogel J, Elmongy H, et al. First clinical report of pencil beam scanned proton therapy for mediastinal lymphoma [abstract]. Int J Radiat Oncol Biol Phys. 2016;96:E497. doi:10.1016/j.ijrobp.2016.06.1876
   Web of Science ®Google Scholar
• Dedeckova K, Mocikova H, Markova J, et al. T011: proton radiotherapy for mediastinal Hodgkin lymphoma: single institution experience [abstract]. Haematologica. 2016;101:12–13.
   Web of Science ®Google Scholar
• Paganetti H, Giantsoudi D. Relative biologic effectiveness uncertainties and implications for beam arrangements and dose constraints in proton therapy. Semin Radiat Oncol. 2018;28:256–263. doi:10.1016/j.semradonc.2018.02.01029933885
   PubMed Web of Science ®Google Scholar
• Paganetti H. Relative biologic effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, linear energy transfer. Phys Med Biol. 2014;59:R419–R472. doi:10.1088/0031-9155/59/22/R41925361443
   PubMed Web of Science ®Google Scholar
• Cuaron JJ, Chang C, Lovelock M, et al. Exponential increase in relative biological effectiveness along distal edges of proton Bragg peak as measured by deoxyribonucleic acid double-strand breaks. Int J Radiat Oncol Biol Phys. 2016;95:62–69. doi:10.1016/j.ijrobp.2016.02.01827084629
   PubMed Web of Science ®Google Scholar
• International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting proton-beam therapy. ICRU Report 78. 1996.
   Google Scholar
• Pagnetti H. Relating proton treatments to photon treatments via the relative biological effectiveness – should we revise current clinical practice? Int J Radiat Oncol Biol Phys. 2015;91:892–894. doi:10.1016/j.ijrobp.2014.11.02125832682
   PubMed Web of Science ®Google Scholar
• Dabaja BS, Mikhaeel G. In the battle between protons and photons for hematologic malignancies, the patient must win. Int J Radiat Oncol Biol Phys. 2015;95:43–45. doi:10.1016/j.ijrobp.2015.09.043
   Web of Science ®Google Scholar
• Eley JG, Newhauser WD, Ritcher D, Luchtenborg R, Saito N, Bert C. Robustness of target dose coverage to motion uncertainties for scanned carbon ion beam tracking therapy of moving tumors. Phys Med Biol. 2015;60:1717–1740. doi:10.1088/0031-9155/60/4/171725650520
   PubMed Web of Science ®Google Scholar
• Eley JG, Newhauser WD, Luchtenborg R, Graeff C, Bert C. 4D optimization of scanned ion beam tracking therapy for moving tumors. Phys Med Biol. 2014;59:3431–3452. doi:10.1088/0031-9155/59/13/343124889215
   PubMed Web of Science ®Google Scholar
• Levis M, De Luca V, Fiandra C, et al. Plan optimization for mediastinal radiotherapy: estimation of coronary arteries motion with ECG-gated cardiac imaging and creation of compensatory expansion margins. Radioth Oncol. 2018;127:481–486. doi:10.1016/j.radonc.2018.04.014
   PubMed Web of Science ®Google Scholar
• Levis M, Filippi AR, Fiandra C, et al. Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin’s lymphoma patients. Radioth Oncol. 2019;138:52–58. doi:10.1016/j.radonc.2019.05.009
   PubMed Web of Science ®Google Scholar
• Rechner LA, Maraldo MV, Vogelius IR, et al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: the impact of proton therapy and/or deep inspiration breath hold. Radioth Oncol. 2017;125:41–47. doi:10.1016/j.radonc.2017.07.033
   PubMed Web of Science ®Google Scholar
• Baues C, Marnitz S, Engert A, et al. Proton versus photon deep inspiration breath hold technique in pateints with Hodgkin lymphoma and mediastinal radiation. Radiat Oncol. 2018;13:122. doi:10.1186/s13014-018-1066-229970105
   PubMed Web of Science ®Google Scholar
• Everett AS, Hoppe BS, Louis D, et al. Comparison of techniques for involved-site radiation therapy in patients with lower mediastinal lymphoma. Pract Radiat Oncol. 2019. doi:10.1016/j.prro.2019.05.009
   PubMed Web of Science ®Google Scholar
• Li J, Dabaja BS, Reed V, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys. 2011;81:167–174. doi:10.1016/j.ijrobp.2010.05.00720643518
   PubMed Web of Science ®Google Scholar
• Knausl B, Lutgendorf-Caucig C, Hopfgartner J, et al. Can treatment of pediatric Hodgkin’s lymphoma be improved by PET imaging and proton therapy? Strahlenther Onkol. 2013;189:54–61. doi:10.1007/s00066-012-0235-823161118
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Flampouri S, Su Z, et al. Consolidative involved-node proton therapy for stage I-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys. 2012;83:260–267. doi:10.1016/j.ijrobp.2011.06.195922014950
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;84:449–455. doi:10.1016/j.ijrobp.2011.12.03422386373
   PubMed Web of Science ®Google Scholar
• Sachsman S, Hoppe BS, Mendenhall NP, et al. Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma. Leuk Lymphoma. 2015;56:2019–2024. doi:10.3109/10428194.2014.97580225315071
   PubMed Web of Science ®Google Scholar
• Jørgensen AY, Maraldo MV, Brodin NP, et al. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin’s lymphoma. Acta Oncol. 2013;52:1559–1565. doi:10.3109/0284186X.2013.81363624047340
   PubMed Web of Science ®Google Scholar
• Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24:113–118. doi:10.1093/annonc/mdt156
   Web of Science ®Google Scholar
• Maraldo MV, Brodin NP, Aznar MC, et al. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment? Int J Radiat Oncol Biol Phys. 2013;87:297–303. doi:10.1016/j.ijrobp.2013.06.00423910709
   PubMedGoogle Scholar
• Maraldo MV, Brodin NP, Aznar MC, et al. Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy. Radiother Oncol. 2014;110:441–447. doi:10.1016/j.radonc.2013.09.02724188865
   PubMed Web of Science ®Google Scholar
• Zeng C, Plastaras JP, James P, et al. Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment. Acta Oncol. 2016;55:1132–1138. doi:10.1080/0284186X.2016.119166527332881
   PubMed Web of Science ®Google Scholar
• Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75:1173–1180. doi:10.1016/j.ijrobp.2008.12.04819386423
   PubMed Web of Science ®Google Scholar
• Horn S, Fournier-Bidoz N, Pernin V, et al. Comparison of passive-beam, proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin’s lymphoma female patients receiving involved-field or involved site radiation therapy. Cancer Radiother. 2016;20:98–103. doi:10.1016/j.canrad.2015.11.00226992750
   PubMed Web of Science ®Google Scholar
• Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015;92:175–182. doi:10.1016/j.ijrobp.2015.02.01025863764
   PubMed Web of Science ®Google Scholar
• Filippi AR, Ragona R, Piva C, et al. Optimized volumetric modulated arc therapy versus 3d-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk. Int J Radiat Oncol Biol Phys. 2015;92:161–168. doi:10.1016/j.ijrobp.2015.02.03025863763
   PubMed Web of Science ®Google Scholar
• Aznar MC, Maraldo MV, Schut DA, et al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys. 2015;92:169–174. doi:10.1016/j.ijrobp.2015.01.01325754634
   PubMed Web of Science ®Google Scholar
• Brodin NP, Maraldo MV, Aznar MC, et al. Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2014;88:433–445. doi:10.1016/j.ijrobp.2013.10.02824321783
   PubMed Web of Science ®Google Scholar
• Pinnix CC, Cella L, Andraos TY, et al. Predictors of hypothyroidism in Hodgkin lymphoma survivors after intensity modulated versus 3-dimensional radiation therapy. Int J Radiat Oncol Biol Phys. 2018;101:530–540. doi:10.1016/j.ijrobp.2018.03.00329681481
   PubMed Web of Science ®Google Scholar